338 related articles for article (PubMed ID: 11344629)
1. [Monitoring minimal residual disease in patients with hairy cell leukemia in complete remission after treatment with 2-chlorodioxyadenosine].
Zák P; Chrobák L; Dĕdic K; Podzimek K
Vnitr Lek; 2000 Oct; 46(10):697-703. PubMed ID: 11344629
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine.
Konwalinka G; Schirmer M; Hilbe W; Fend F; Geisen F; Knoblechner A; Petzer A; Thaler J
Blood Cells Mol Dis; 1995; 21(2):142-51. PubMed ID: 8846043
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
Tallman MS; Hakimian D; Kopecky KJ; Wheaton S; Wollins E; Foucar K; Cassileth PA; Habermann T; Grever M; Rowe JM; Peterson LC
Clin Cancer Res; 1999 Jul; 5(7):1665-70. PubMed ID: 10430066
[TBL] [Abstract][Full Text] [Related]
4. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
[TBL] [Abstract][Full Text] [Related]
5. [Bone marrow changes in patients with hairy cell leukemia after 2-chlorodeoxyadenosine treatment].
Urasiński I; Zdziarska B; Krygier-Stojałowska A
Acta Haematol Pol; 1996; 27(1):49-55. PubMed ID: 8629443
[TBL] [Abstract][Full Text] [Related]
6. Cladribine in hairy cell leukemia.
Belani R; Saven A
Hematol Oncol Clin North Am; 2006 Oct; 20(5):1109-23. PubMed ID: 16990111
[TBL] [Abstract][Full Text] [Related]
7. [Hairy cell leukemia. An alternative method for the detection of minimal residual disease using flow cytometry].
Bengio R; Narbaitz M; Palacios F; Scolnik M; Sarmiento M
Medicina (B Aires); 2000; 60 Suppl 2():71-6. PubMed ID: 11188936
[TBL] [Abstract][Full Text] [Related]
8. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
Rucińska M; Machaczka M; Załuska A; Skotnicki AB
Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885
[TBL] [Abstract][Full Text] [Related]
9. [Results of treatment in patients with hairy cell leukemia with splenectomy, alpha-interferon and deoxycoformycin].
Gotić M; Rolović Z; Radosević N; Draguljac N; Jovanović V; Bogdanović A; Bosković D
Srp Arh Celok Lek; 2000; 128(7-8):262-70. PubMed ID: 11089434
[TBL] [Abstract][Full Text] [Related]
10. Rituximab as treatment for minimal residual disease in hairy cell leukaemia.
Cervetti G; Galimberti S; Andreazzoli F; Fazzi R; Cecconi N; Caracciolo F; Petrini M
Eur J Haematol; 2004 Dec; 73(6):412-7. PubMed ID: 15522063
[TBL] [Abstract][Full Text] [Related]
11. Dyserythropoietic changes and sideroblastic anemia in patients with hairy cell leukemia before and after therapy with 2-chlorodeoxyadenosine.
Zák P; Chrobák L; Podzimek K; Plísková L; Dedic K
Neoplasma; 1998; 45(4):261-5. PubMed ID: 9890671
[TBL] [Abstract][Full Text] [Related]
12. The degree of bone marrow infiltration in patients with hairy cell leukemia treated with splenectomy compatible with long-term hematological remission.
Zák P; Chrobák L; Dedic K
Neoplasma; 2001; 48(1):72-5. PubMed ID: 11327542
[TBL] [Abstract][Full Text] [Related]
13. [Detection of minimal residual disease in patients with acute myeloid leukemia].
Gal'tseva IV; Savchenko VG; Kulikov SM; Parovichnikova EN; Miterev GIu; Maslova ER; Isaev VG
Ter Arkh; 2003; 75(7):8-14. PubMed ID: 12934474
[TBL] [Abstract][Full Text] [Related]
14. [Immunohistochemical detection and quantification of minimal residual disease using DBA.44 antibodies in trephination biopsies of hairy cell leukemia].
Dĕdic K; Zák P
Cesk Patol; 2003 Oct; 39(4):175-7. PubMed ID: 14663929
[TBL] [Abstract][Full Text] [Related]
15. Effect of 2-chlorodeoxyadenosine therapy on bone marrow fibrosis in hairy cell leukemia.
Dedic K; Zák P
Neoplasma; 2004; 51(1):56-8. PubMed ID: 15004661
[TBL] [Abstract][Full Text] [Related]
16. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine).
Füreder W; Weltermann A; Chott A; Gisslinger H; Valent P; Jäger U; Geissler K; Lechner K
Wien Klin Wochenschr; 1999 Dec; 111(24):1027-30. PubMed ID: 10677889
[TBL] [Abstract][Full Text] [Related]
17. A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission.
Filleul B; Delannoy A; Ferrant A; Zenebergh A; Van Daele S; Bosly A; Doyen C; Mineur P; Glorieux P; Driesschaert P
Leukemia; 1994 Jul; 8(7):1153-6. PubMed ID: 7913513
[TBL] [Abstract][Full Text] [Related]
18. [Hairy cell leukemia, Japanese variant, successfully treated with cladribine].
Miyazaki M; Taguchi A; Sakuragi S; Mitani N; Matsuda K; Shinohara K
Rinsho Ketsueki; 2004 May; 45(5):405-7. PubMed ID: 15199752
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of complete remission in hairy cell leukemia patients treated with alpha-IFN.
Lauria F; Foà R; Raspadori D; Pileri S; Tassinari A; Buzzi M; Zaccaria A; Zinzani PL; Tura S
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():176-8. PubMed ID: 2785426
[TBL] [Abstract][Full Text] [Related]
20. Use of image analysis and immunostaining of bone marrow trephine biopsy specimens to quantify residual disease in patients with B-cell chronic lymphocytic leukemia.
Gala JL; Guiot Y; Delannoy A; Scheiff JM; Philippe M; Martiat P
Mod Pathol; 1999 Apr; 12(4):391-9. PubMed ID: 10229504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]